Pharvaris (NASDAQ:PHVS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Pharvaris (NASDAQ:PHVS) from a sell rating to a hold rating in a report released on Saturday.

Other equities research analysts have also recently issued reports about the company. Leerink Partners set a $38.00 price objective on Pharvaris in a research note on Wednesday, December 3rd. Guggenheim increased their target price on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Tuesday, March 3rd. Bank of America lifted their target price on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Thursday, December 4th. Finally, Royal Bank Of Canada started coverage on shares of Pharvaris in a research note on Monday, March 9th. They set an “outperform” rating and a $52.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $41.70.

Pharvaris Stock Down 0.1%

Shares of NASDAQ PHVS opened at $27.35 on Friday. The business’s 50 day moving average is $26.91 and its two-hundred day moving average is $25.25. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.80. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -8.52 and a beta of -2.78.

Institutional Trading of Pharvaris

Several hedge funds have recently modified their holdings of PHVS. GF Fund Management CO. LTD. purchased a new position in Pharvaris in the fourth quarter valued at $35,000. Barclays PLC purchased a new stake in Pharvaris during the 4th quarter worth about $77,000. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris in the 3rd quarter valued at about $75,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pharvaris in the 4th quarter valued at about $86,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.